Is the FDA protecting the public from harmful drugs?
Article Abstract:
Sandra Kweder, Deputy Director of U.S. Food and Drug Administration (FDA), debates with David Graham, Associate Director of U.S. FDA, on whether the FDA is protecting the public from harmful drugs. Kweder believes that FDA created a strong post-market drug-safety program designed to assess adverse events while Graham feels that whenever a serious safety issue arises post-marketing, FDA's immediate reaction is almost one of denial, rejection and heat.
Publication Name: CQ Researcher
Subject: News, opinion and commentary
ISSN: 1056-2036
Year: 2005
User Contributions:
Comment about this article or add new information about this topic:
Access to information
Article Abstract:
Drug Safety Oversight Board will establish a new Drug Watch Web Page on the Internet, which will provide the public with emerging information about safety, issues that may alter the risk or benefit analysis of a drug. One-page information will also be provided for all drugs, offering basic information and safety updates in a consumer-friendly format.
Publication Name: CQ Researcher
Subject: News, opinion and commentary
ISSN: 1056-2036
Year: 2005
User Contributions:
Comment about this article or add new information about this topic: